A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma

In brief

To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.

Key facts

Study ID
NCT03520959
Run by
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
People needed
1
Starts
2018-09-18
Expected to finish
2018-11-20
Last updated by the study team
2020-04-16

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.